PNAS:螺内酯有望治疗心衰的同时治疗EBV感染

2016-03-15 MedSci MedSci原创

1996年医学微生物学相关报道指出,世界上已知的疱疹病毒超过100种,其中8种对人类影响重大。 单纯疱疹病毒1型(HSV-1)是导致民众嘴唇起疱疹的主要原因。HSV-2引起生殖器部位出现并形成水泡或溃疡。HSV-3或带状疱疹病毒可能导致民众患水痘和带状疱疹。 HSV-4也叫做EB病毒(EBV),导致民众患传染性单核细胞增多症,俗称“接吻病”,因为它往往通过唾液传播。EBV还与其他一些疾病如癌症等密

1996年医学微生物学相关报道指出,世界上已知的疱疹病毒超过100种,其中8种对人类影响重大。

单纯疱疹病毒1型(HSV-1)是导致民众嘴唇起疱疹的主要原因。HSV-2引起生殖器部位出现并形成水泡或溃疡。HSV-3或带状疱疹病毒可能导致民众患水痘和带状疱疹。

HSV-4也叫做EB病毒(EBV),导致民众患传染性单核细胞增多症,俗称“接吻病”,因为它往往通过唾液传播。EBV还与其他一些疾病如癌症等密切相关。接受移植手术及免疫系统受损的患者感染EBV的风险增加。

CDC指出,EBV的感染是世界范围内的,是最常见感染人类的病毒之一。他们指出,大多数民众都携带有EBV,但无明显症状。仅有一种类抗病毒药物可用于治疗疱疹病毒。

以Sankar Swaminathan为首的犹他大学医学院的科学家们一直在寻找新的药物来治疗病毒感染。当今的药物通过阻止病毒DNA的复制而抑制病毒的感染。

研究人员发现,螺内酯(SPR)可抑制SM蛋白的形成而抑制病毒复制过程。

基于这些发现,研究人员认为SPR可作为抑制EBV病毒复制的新型药物。

Swaminathan博士指出,SPR通常用于治疗心力衰竭,但在处理EBV病毒感染时它也可发挥一定的作用。但其他类似SPR的药物在治疗心力衰竭时并不能抑制疱疹病毒的复制。这些结果表明,螺内酯的研究前景十分广阔。

原始出处:

Verma D, Thompson J, Swaminathan S. Spironolactone blocks Epstein-Barr virus production by inhibiting EBV SM protein function. Proc Natl Acad Sci U S A. 2016 Mar 14. pii: 201523686

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1855817, encodeId=4dee185581e43, content=<a href='/topic/show?id=f32014428fc' target=_blank style='color:#2F92EE;'>#PNAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14428, encryptionId=f32014428fc, topicName=PNAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Mon Dec 05 20:39:00 CST 2016, time=2016-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=72678, encodeId=b7dde2678d4, content=学习了了解了, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44b91679772, createdName=1de304d2m86(暂无匿称), createdTime=Tue Mar 22 13:06:00 CST 2016, time=2016-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=71854, encodeId=248ae1854ec, content=螺内酯可以抑制EB病毒, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160227/IMG56D1078DD4F344111.jpg, createdBy=80b71692457, createdName=壹生, createdTime=Sun Mar 20 09:00:00 CST 2016, time=2016-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=71853, encodeId=d065e1853de, content=了解HSV-1HSV-2HSV-3HSV-4,学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160227/IMG56D1078DD4F344111.jpg, createdBy=80b71692457, createdName=壹生, createdTime=Sun Mar 20 08:57:00 CST 2016, time=2016-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480778, encodeId=787d1480e78a5, content=<a href='/topic/show?id=cce3646351' target=_blank style='color:#2F92EE;'>#EBV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6463, encryptionId=cce3646351, topicName=EBV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1227684795, createdName=zjshifan_98647308, createdTime=Thu Mar 17 06:39:00 CST 2016, time=2016-03-17, status=1, ipAttribution=)]
    2016-12-05 drwjr
  2. [GetPortalCommentsPageByObjectIdResponse(id=1855817, encodeId=4dee185581e43, content=<a href='/topic/show?id=f32014428fc' target=_blank style='color:#2F92EE;'>#PNAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14428, encryptionId=f32014428fc, topicName=PNAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Mon Dec 05 20:39:00 CST 2016, time=2016-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=72678, encodeId=b7dde2678d4, content=学习了了解了, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44b91679772, createdName=1de304d2m86(暂无匿称), createdTime=Tue Mar 22 13:06:00 CST 2016, time=2016-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=71854, encodeId=248ae1854ec, content=螺内酯可以抑制EB病毒, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160227/IMG56D1078DD4F344111.jpg, createdBy=80b71692457, createdName=壹生, createdTime=Sun Mar 20 09:00:00 CST 2016, time=2016-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=71853, encodeId=d065e1853de, content=了解HSV-1HSV-2HSV-3HSV-4,学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160227/IMG56D1078DD4F344111.jpg, createdBy=80b71692457, createdName=壹生, createdTime=Sun Mar 20 08:57:00 CST 2016, time=2016-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480778, encodeId=787d1480e78a5, content=<a href='/topic/show?id=cce3646351' target=_blank style='color:#2F92EE;'>#EBV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6463, encryptionId=cce3646351, topicName=EBV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1227684795, createdName=zjshifan_98647308, createdTime=Thu Mar 17 06:39:00 CST 2016, time=2016-03-17, status=1, ipAttribution=)]
    2016-03-22 1de304d2m86(暂无匿称)

    学习了了解了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1855817, encodeId=4dee185581e43, content=<a href='/topic/show?id=f32014428fc' target=_blank style='color:#2F92EE;'>#PNAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14428, encryptionId=f32014428fc, topicName=PNAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Mon Dec 05 20:39:00 CST 2016, time=2016-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=72678, encodeId=b7dde2678d4, content=学习了了解了, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44b91679772, createdName=1de304d2m86(暂无匿称), createdTime=Tue Mar 22 13:06:00 CST 2016, time=2016-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=71854, encodeId=248ae1854ec, content=螺内酯可以抑制EB病毒, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160227/IMG56D1078DD4F344111.jpg, createdBy=80b71692457, createdName=壹生, createdTime=Sun Mar 20 09:00:00 CST 2016, time=2016-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=71853, encodeId=d065e1853de, content=了解HSV-1HSV-2HSV-3HSV-4,学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160227/IMG56D1078DD4F344111.jpg, createdBy=80b71692457, createdName=壹生, createdTime=Sun Mar 20 08:57:00 CST 2016, time=2016-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480778, encodeId=787d1480e78a5, content=<a href='/topic/show?id=cce3646351' target=_blank style='color:#2F92EE;'>#EBV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6463, encryptionId=cce3646351, topicName=EBV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1227684795, createdName=zjshifan_98647308, createdTime=Thu Mar 17 06:39:00 CST 2016, time=2016-03-17, status=1, ipAttribution=)]
    2016-03-20 壹生

    螺内酯可以抑制EB病毒

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1855817, encodeId=4dee185581e43, content=<a href='/topic/show?id=f32014428fc' target=_blank style='color:#2F92EE;'>#PNAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14428, encryptionId=f32014428fc, topicName=PNAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Mon Dec 05 20:39:00 CST 2016, time=2016-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=72678, encodeId=b7dde2678d4, content=学习了了解了, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44b91679772, createdName=1de304d2m86(暂无匿称), createdTime=Tue Mar 22 13:06:00 CST 2016, time=2016-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=71854, encodeId=248ae1854ec, content=螺内酯可以抑制EB病毒, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160227/IMG56D1078DD4F344111.jpg, createdBy=80b71692457, createdName=壹生, createdTime=Sun Mar 20 09:00:00 CST 2016, time=2016-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=71853, encodeId=d065e1853de, content=了解HSV-1HSV-2HSV-3HSV-4,学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160227/IMG56D1078DD4F344111.jpg, createdBy=80b71692457, createdName=壹生, createdTime=Sun Mar 20 08:57:00 CST 2016, time=2016-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480778, encodeId=787d1480e78a5, content=<a href='/topic/show?id=cce3646351' target=_blank style='color:#2F92EE;'>#EBV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6463, encryptionId=cce3646351, topicName=EBV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1227684795, createdName=zjshifan_98647308, createdTime=Thu Mar 17 06:39:00 CST 2016, time=2016-03-17, status=1, ipAttribution=)]
    2016-03-20 壹生

    了解HSV-1HSV-2HSV-3HSV-4,学习了!

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1855817, encodeId=4dee185581e43, content=<a href='/topic/show?id=f32014428fc' target=_blank style='color:#2F92EE;'>#PNAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14428, encryptionId=f32014428fc, topicName=PNAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Mon Dec 05 20:39:00 CST 2016, time=2016-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=72678, encodeId=b7dde2678d4, content=学习了了解了, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44b91679772, createdName=1de304d2m86(暂无匿称), createdTime=Tue Mar 22 13:06:00 CST 2016, time=2016-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=71854, encodeId=248ae1854ec, content=螺内酯可以抑制EB病毒, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160227/IMG56D1078DD4F344111.jpg, createdBy=80b71692457, createdName=壹生, createdTime=Sun Mar 20 09:00:00 CST 2016, time=2016-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=71853, encodeId=d065e1853de, content=了解HSV-1HSV-2HSV-3HSV-4,学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160227/IMG56D1078DD4F344111.jpg, createdBy=80b71692457, createdName=壹生, createdTime=Sun Mar 20 08:57:00 CST 2016, time=2016-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480778, encodeId=787d1480e78a5, content=<a href='/topic/show?id=cce3646351' target=_blank style='color:#2F92EE;'>#EBV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6463, encryptionId=cce3646351, topicName=EBV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1227684795, createdName=zjshifan_98647308, createdTime=Thu Mar 17 06:39:00 CST 2016, time=2016-03-17, status=1, ipAttribution=)]

相关资讯

AHA 2013:螺内酯对射血分数正常心衰患者中的疗效

于AHA 2013科学年会公布的TOPCAT研究表明,在射血分数正常心衰患者(HFPEF)中,醛固酮受体拮抗剂螺内酯治疗对临床复合主要终点未产生获益,但显著减少了心衰住院。此项研究从6个国家共纳入3445例左室射血分数(LVEF)>45%的心衰患者(年龄>50岁),并随机给予其醛固酮拮抗剂或安慰剂治疗。螺内酯被逐步增加剂量至30~45 mg/d。平均随访时间为3.3年。主要终

ESC 2015:螺内酯——难治性高血压中老树新花(PATHWAY-2研究)

今年ESC 2015年会的高血压Hotline专场,研究者Bryan William教授发布了PATHWAY-2研究的结果。Bryan William教授总结道,本研究第一次证实了螺内酯(25~50mg/d)在治疗难治性高血压方面相对于其他药物绝对优势。对于难治性高血压的控制率几乎达到60%,显著高于其他几组。且其耐受性良好,并未增加不良事件的发生。研究者评价道,该研究结果提示,螺内酯是难治性高血

螺内酯为主的联合药物治疗原发性醛固酮增多症疗效佳

为了解非手术治疗的原发性醛固酮增多症(PA)患者经药物治疗后的预后,朱理敏,龚艳春,林伯贤等进行研究发现,未经手术的PA患者经以螺内酯为主的联合药物治疗可以有效降低血压,纠正低血钾,但有升高血糖的趋势。相关论文发表于2013年第6期《中华高血压杂志》。 研究纳入2012-01-05在高血压门诊随访的PA患者186例,依据患者随访时是否使用螺内酯治疗分为螺内酯组和常规药物组。以螺内酯为主的联合药物

NEJM:射血分数保留型心衰,螺内酯无治疗作用

摘自2014年4月10日刊N Engl J Med:----------------------------------标题:螺内酯治疗射血分数保留型心衰(TOPCAT临床实验)背景:盐皮质激素受体拮抗剂改善了左心室射血分数下降型心力衰竭患者的预后。我们评估了螺内酯用于左心室射血分数保留型心衰的作用。方法:这项随机、双盲试验共纳入3445名症状性心衰患者,其左心室射血分数均高于45%或以上,分别接

Lancet Diab & Endo:刀尖上的舞蹈—盐皮质激素受体拮抗剂在CKD患者中的应用

2010全球疾病负担排行中,慢性肾脏病(CKD)被定义为1990-2010年间增长最快的三大致死性疾病之一。CKD患者有着高于常人3-5倍的心血管事件风险。心血管事件是CKD患者最常见的患病形式和死亡形式,尽管CKD患者面临着如此严峻的生存挑战,现在对CKD透析患者心血管疾病发病有效的预防管理方案。人们的注意力逐渐转移到盐皮质激素受体拮抗剂上(如螺内酯,依普利酮),之所以对CKD及透析患者应用盐皮

Lancet:治疗耐药性高血压,螺内酯更有效!

治疗耐药性高血压患者的最佳药物是不确定的。该研究的目的是测试,假设高血压是最常见的原因是钠滞留钠滞留过多,因此螺内酯将在降低血压方面优于非利尿附加药物。在这项双盲,安慰剂对照,交叉试验中,研究人员招募了年龄在18-79岁,门诊收缩压为140mm Hg或更高(或≥135mm Hg的糖尿病患者)和家庭收缩压(超过4天读数18次)为130mm Hg或更高的患者,他们接受至少3个月的最大耐受剂量的三种药物